U.S. Markets open in 7 hrs 9 mins

Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation

SAN DIEGO, Feb. 18, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation, as detailed below:

Clovis Oncology, Inc.

Johnson & Weaver, LLP is investigating potential violations of federal and state securities laws by Clovis Oncology, Inc. (CLVS) and certain of its officers.

On November 19, 2015, a class action lawsuit was filed against Clovis over alleged securities laws violations. If you have held shares continuously prior to May 31, 2014, you may have standing to hold Clovis harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a Clovis shareholder, have held shares continuously prior to May 31, 2014, and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.

USANA Health Sciences, Inc.

Johnson & Weaver, LLP is investigating potential violations of federal and state securities laws by USANA Health Sciences, Inc. (USNA) and certain of its officers.

A class action lawsuit has been filed on behalf of purchasers of USANA from March 14, 2014 through February 7, 2017, both dates inclusive (the "Class Period"). If you wish to serve as a lead plaintiff, you must move the Court no later than April 14, 2017.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects.

If you have held shares continuously prior to March 14, 2014, you may have standing to hold USANA harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a USANA shareholder, have held shares continuously prior to March 14, 2014, and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.

Anthera Pharmaceuticals, Inc.

Shareholder Rights Law Firm Johnson & Weaver, LLP announces the filing of a class action lawsuit on behalf of purchasers of Anthera Pharmaceuticals, Inc. (ANTH)  from February 10, 2015 through December 27, 2016, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for Anthera investors under the federal securities laws.

According to the lawsuit, throughout the Class Period, Anthera made materially false and/or misleading statements concerning the potential efficacy and success of its Solution Study and CHABLIS-SC1 clinical trials, as the Company failed to disclose that: (1) patients were not improving in the CHABLIS-SC1 clinical trial; and (2) there were dosing problems inherent in the Solution Study design that created challenges to obtaining responses.

On November 10, 2016, the Company issued a press release announcing that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of SLE failed to meet its primary endpoint. Then on December 27, 2016, the Company issued another press release, announcing that the Solution clinical study in cystic fibrosis patients with EPI missed the CFA non-inferiority margin of the primary modified Intent to Treat. Following this disclosure, shares of Anthera plummeted approximately 63% on December 28, 2016.

 If you wish to serve as a lead plaintiff, you must move the Court no later than April 17, 2017.  If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. Your ability to share in any recovery does not require that you serve as a lead plaintiff.

PixarBio Corporation

Shareholder Rights Law Firm Johnson & Weaver, LLP announces the filing of a class action lawsuit on behalf of purchasers of PixarBio Corporation (PXRB)  from October 31, 2016 through January 20, 2017, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for PixarBio investors under the federal securities laws.

According to the lawsuit, PixarBio made false and misleading statements and failed to disclose that: (1) the market for PixarBio's securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio's Form S-1 lacked accuracy; and (3) as a result, the Company's public statements were materially false and misleading.

On January 23, 2017, the Securities and Exchange Commission announced the temporary suspension of PixarBio trading stating, relatively, that "the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1."

If you wish to serve as a lead plaintiff, you must move the Court no later than March 27, 2017.  If you wish to discuss this action, have any questions concerning this notice, or your rights or interests, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471. Your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com

Johnson & Weaver LLP

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--weaver-llp-announces-investigations-of-clovis-oncology-inc-usana-health-sciences-inc-anthera-pharmaceuticals-inc-and-pixarbio-corporation-300409876.html